Abstract: Rituximab efficacy in cancer therapy depends in part on induction of complement-dependent cytotoxicity (CDC). Human CD59 (hCD59) is a key complement regulatory protein that restricts the formation of the membrane attack complex, thereby inhibiting induction of CDC. hCD59 is highly expressed in B-cell non-Hodgkin's lymphoma (NHL) and up-regulation of hCD59 is an important determinant of the sensitivity of NHL cells to rituximab treatment. Here we report that the potent hCD59 inhibitor rILYd4 enhances CDC in vitro and in vivo, thereby sensitizing rituximabresistant lymphoma cells and primary chronic lymphocytic leukemia cells (CLL) to rituximab treatment. By defining PK/PD profiles of rILYd4 in mice, we showed that by itself rILYd4 does not adversely mediate in vivo hemolysis of hCD59-expressing erythrocytes. Increasing expression levels of the complement regulators CD59 and CD55 in rituximab-resistant cells occurs due to selection of pre-existing clones, rather than de novo induction of these proteins. Moreover, lymphoma cells overexpressing CD59 were directly responsible for the resistance to rituximab-mediated CDC therapy.
Introduction
In the last 10 years, the chimeric antibody of rituximab, which specifically targets CD20 on the B lymphocyte membrane, has led to significant progress in the treatment of B-cell non-Hodgkin's lymphoma (NHL)(1). However, a subset of NHL patients do not respond to rituximab, despite expressing CD20 (2) , and many patients who initially respond develop resistance to further treatment over time (3) . The mechanisms suspected to mediate rituximab's therapeutic effect include 1) complement-dependent cytotoxicity (CDC)(4-7); 2) antibody-dependent cellular cytotoxicity (ADCC) (2, (8) (9) (10) involving phagocytosis (11) and/or Fc:FcR dependent mechanisms(12); and 3) apoptosis(1, 9, 12).
The role of the CDC on rituximab-mediated lymphoma therapy has been extensively investigated in vivo and in vitro (9) . Complement depletion by cobra venom factor or C1q-deficiency significantly reduces the antitumor activity of rituximab in mouse models (6, (13) (14) (15) . Consistently, complement consumption has been observed in vitro and in vivo after rituximab administration(5, 16) , and addition of fresh frozen plasma as a source of complement is able to increase the therapeutic response to rituximab in refractory-CLL patients (17, 18) . The importance of CDC in B-cell lymphoma response to rituximab was further confirmed by the finding that antibodies that abrogate The complement system is the principal part of the innate immune system and plays an important role in host defense. To prevent the potentially harmful effect of complement activation on normal cells, some mCRPs including CD46, CD55 and CD59 have evolved to restrict complement activation at different stages of the complement cascades (9, 25) . CD59, a glycosylphosphatidylinositol (GPI)-anchored mCRP, restricts formation of the membrane attack complex (MAC) by preventing C9 polymerization through binding to C8 and C9 (26) . CD55, another GPI-anchored mCRP, inactivates the C3 and C5 convertases by accelerating the decay of those proteases (27) (28) (29) , while CD46, a non GPI-anchored membrane protein, acts as a cofactor for inactivation of cellbound C4b and C3b by serum factor I (30) . Not only do these mCRPs protect normal cells from bystander complement attack, but they also confer protection to cancer cells by limiting complement activation by a therapeutic antibody such as rituximab.
Numerous findings indicate that CD59 is the most effective mCRP protecting B cell lymphomas from rituximab-mediated CDC (2, 4, 21, 31) . Dalle (32) . Moreover, in a clinical study of chronic lymphocytic leukemia (CLL), Bannerji et al found a significant increase in hCD59 expression in patients who failed to clear CLL cells from peripheral blood after initiation of rituximab treatment (33) . Taken together, these results suggest that the over-expression of mCRPs, and especially CD59, contributes to the resistance of lymphoma and CLL cells to rituximab therapy (34, 35 were generated by crossing the mCd59a and mCd59b knockout mouse (mCd59ab -/-)(37) with a hCD59 transgenic mouse (ThCD59 These cell lines were authenticated by the supplier, obtained within 6 months of their use, and passaged less than 50 times. We did not re-authenticate the cell lines.
The CLL patients had been previously enrolled on Dana-Farber Harvard Cancer Center (DFHCC) protocol 99-224. All participants signed informed consent prior to sample collection. The blood from CLL patients was then separated on a Ficoll gradient and peripheral blood mononuclear cells (PBMCs) were frozen. The frozen PBMCs from six patients participating in this study (supplementary Table 1 ) were cultured in IMDM medium (Invitrogen) supplemented with 10% human AB serum (GemCell, Gemini Co., West Sacramento, CA), 50 μg/ml transferrin (Roche Applied Science, Indianapolis, IN), 5 μg/ml human insulin (Roche Applied Science, Indianapolis, IN), 100 U/ml penicillin and 100 μg/ml streptomycin.
Intact ILY and rILYd4 tagged with HisX6 at its N-terminals were purified as described in (36, 38) .
Generation of RR and hCD59 negative Ramos cell lines
We used a previously reported procedure (31) 
Data analysis
The differences between means of paired samples on primary CLL cells was evaluated by Wilcoxon's signed rank test. In the other experiments, the comparison between two or three groups was examined with a nonparametric Mann-Whitney test. A P value <0.05 was considered significant. Figure 3) . This observation suggests that CD20 level may be associated with the sensitivity to rILYd4 treatment. Taken together, these results indicate that rILYd4 sensitizes RR NHL and CLL cells to rituximab-mediated CDC in vitro and ex vivo, respectively.
2D and Supplementary

Potential mechanism of up-regulation of CD59 in RR Ramos cells
Here, we document that the levels of GPI-anchored proteins such as mCRPs CD59 
CD46, CD59, CD55 and CD48 ( Figure 3A) at a similar level and had the same sensitivity to rituximab-mediated CDC as the RR51.2 cells did ( Figure 1A , 2B, 3C and Supplementary Figure 1) . In addition, rILYd4 also sensitized CD59-enriched CS cells to rituximab-mediated CDC in a dose-dependent manner ( Figure 3D) . Furthermore, the CD59 negative subpopulation obtained from ILY-treated CS cells ( Figure 3B ) was sensitive to rituximab-mediated CDC ( Figure 3E ). Taken 
rILYd4 sensitizes RR51.2 cells to rituximab-mediated CDC effect in vivo
Next, we used both developing and established orthotopic xenograft models to investigate whether rILYd4 sensitizes RR Ramos cells to rituximab treatment in vivo.
We implanted RR51.2 cells into nude mice following published protocols (39, 40 
the adjuvant rILYd4 dramatically slowed down tumor growth as compared with rituximab alone ( Figure 4A ). Importantly, treatment with only rILYd4 did not affect tumor growth significantly ( Figure 4A) . A similar observation was also made in the established xenograft model where combination treatment with rituximab and the adjuvant rILYd4 resulted in significant reduction in tumor size as compared with treatment with rituximab alone ( Figure 4B) . Further, the tumor-free rates in the established xenograft model after treatment with vehicle, rILYd4 alone, rituximab alone and combination of rituximab with rILYd4 were 0%, 0%, 8.3% and 50%, respectively, suggesting treatment with rILYd4 as adjuvant can lead to elimination of tumor in 50% of the animals ( Figure 4C ).
PK/PD profiles of rILYd4
The circulating half life and volume of distribution of rILYd4 were determined after tail
RBC+/-mice. The serum level of rILYd4 showed a biphasic decay curve, with a fast initial distribution followed by a slower elimination phase. PK parameters are shown in Figure 5A 
mice.
We have previously reported(36) and also confirmed in this study that rILYd4 alone has no direct lytic effect on hCD59-expressing cells in vitro (Supplementary Figure 2B) . To further assess its toxicity profile in vivo, we utilized mCd59ab
. In an acute toxicity study, we found that there were no significant differences in the levels of 
Discussion
Here, we demonstrate that the administration of rILYd4 abrogates hCD59 function in RR cells and restores the sensitivity of these resistant Ramos and primary
CLL cells to rituximab-mediated CDC effects in vitro, ex vivo and in vivo.
We also document that the hCD59 over-expressing population of Ramos cells is responsible for the resistance to rituximab-mediated CDC in vitro. These results highlight the critical role of CD59 in the development of rituximab resistance, and indicate that rILYd4 may provide a new approach to enhance the therapeutic efficacy of rituximab by abrogating hCD59 activity. These interpretations are also supported by our recent findings that rILYd4 was able to sensitize the lymphoma cell line RL-7 or the multiple myeloma cell line ARH-7 to rituximab-mediated CDC (42) . The role of CDC in rituximab therapy was challenged previously by the findings that the expressions of mCRPs does not predict clinical outcome after rituximab treatment in follicular NHL (43) . Recently, Weiner's group demonstrate that the C3b component of complement could inhibit NK cell activation and ADCC effects during rituximab treatment (10) , and thus C3 depletion improves rituximab antitumor activity (20) . Also, several researches have shown that both CDC and ADCC play major roles in the antitumor activity of rituximab (2, (8) (9) (10) . Furthermore, CDC-resistant cells are sensitive to ADCC and vice versa (9, 14, 44) . Differences in the relative importance of CDC and ADCC following rituximab treatment may result from the different types of tumors used, expression levels of CD20 and mCRP, tumor-inoculating methods, and tumor growth period (9, 11) . Although the investigation of the relative roles of CDC and ADCC is beyond the scope of our studies, it will be very helpful for the future of drug design and therefore warrants further investigation. Since CD59 is universally expressed in human cells with a relative high levels in erythrocytes, potential side effects such as hemolysis are the potential hurdles for the development of clinically-useful hCD59 inhibitors. Monoclonal antibodies directed against hCD59 are useful tools for the study of CD59 function in vitro (4, 19, 31) . In spite CAN-10-3016 anchored proteins including CD59, CD55 and CD48, may result from the positive selection of pre-existing cells that highly express GPI-anchored proteins, rather than from the induction of GPI-anchored proteins. We therefore postulate that tumor heterogeneity may be responsible for the increase in the population of highly expressing CD59 lymphoma cells, a contributor to rituximab resistance. In support of this hypothesis, we demonstrate that two other NHL cell lines (Raji and Daudi) resistant to rituximab-mediated CDC also express a higher level of CD59 than their parental cell lines (Supplementary Figure 5) . Together, these results indicate that the ablation of those pre-existing resistant tumor cells by early treatment with combination of rILYd4 and rituximab may effectively limit the expansion of RR lymphoma cells through the abrogation of this subpopulation of cells expressing high levels of hCD59. Further, rILYd4 may also sensitize tumor cells that have acquired resistance to rituximab after multiple therapies to the anti-cancer activity of rituximab.
We also designed and executed a PK/PD study to evaluate drug exposure and 
that the pre-formed rILYd4-hCD59 interaction on erythrocytes was able to compete with binding of the full length ILY to hCD59 and exert protection against ILY-mediated hemolysis(36). The comparable PK and PD profiles suggest that rILYd4 bound to erythrocytes remains functional throughout the in vivo exposure. These data provide insight and guidance for the further engineering of rILYd4 to better suit biologic therapy.
The toxicity profile is critical for identifying a dosing window to get good efficacy with tolerable side effects. Here, we demonstrate that i.p. injection of 3-fold the effective dose (6 mg/kg, Q4D X 8 times) of rILYd4 did not induce erythrocyte lysis in hCD59 transgenic mice in a mCd59 deficient background. No other notable pathological changes have been observed either. Overall, at the doses tested, rILYd4 did not show any sign of unwanted side effects. It remains to be seen whether other toxic effects emerge upon reaching the maximum tolerated dose in mice. Immunogenicity is another critical aspect for the effective development of a protein drug. Previous findings indicate that rILYd4 has low immunogenicity (45, 46) . However, a low-or even non-immunogenic form of rILYd4 or ILYd4-derived peptides will be essential for clinical application, and requires further investigation and development. 
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